The Federal Antimonopoly Service of Russia settled the prices of Lapatinib-Promomed, the second generic drug with the active ingredient lapatinib. A package of 140 tablets will be priced at 50% less than the foreign reference drug Tyverb, which costs 107,090 rubles. The cost will be significantly reduced to 53,545 rubles.
“The Russian law states that once the prices are registered for the second generic, the registered prices for the first one, specifically Lapatinib-Khimrar in this case, must be decreased by over 15%. The department will be sending a notification to the pharmaceutical manufacturer”, says the FAS press-center.
